Table 2.
Univariate and multivariate Cox regression analyses associated with the risk of overall survival
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p value | HR | 95%CI | p value | |
| Sex, male versus female | 1.22 | 0.44–3.40 | 0.701 | |||
| Age (years) | 0.98 | 0.95–1.01 | 0.242 | |||
| Bodyweight (kg) | 1.00 | 0.98–1.03 | 0.883 | |||
| Radiographic liver cirrhosis | 1.37 | 0.80–2.34 | 0.252 | |||
| Hepatitis etiology | ||||||
| Hepatitis B virus | 0.70 | 0.33–1.49 | 0.358 | |||
| Hepatitis C virus | 1.81 | 0.56–5.84 | 0.322 | |||
| Other | 1.16 | 0.49–2.72 | 0.733 | |||
| ECOG PS | 0.87 | 0.46–1.65 | 0.667 | |||
| 0 | ||||||
| 1 | ||||||
| 2 | ||||||
| Total bilirubin (μmol/L) | 1.00 | 0.99–1.01 | 0.935 | |||
| Albumin (g/L) | 0.98 | 0.90–1.06 | 0.575 | |||
| PT (sec) | 1.00 | 0.84–1.17 | 0.954 | |||
| Child–Pugh score | 1.10 | 0.67–1.79 | 0.707 | |||
| 7 | ||||||
| 8 | ||||||
| 9 | ||||||
| ALBI score | 1.20 | 0.56–2.58 | 0.641 | |||
| ALBI Grade, 2 versus 3 | 1.46 | 0.76–2.79 | 0.252 | |||
| AST (U/L) | 1.00 | 1.00–1.00 | 0.623 | |||
| ALT (U/L) | 1.00 | 1.00–1.00 | 0.923 | |||
| ALP (U/L) | 1.00 | 1.00–1.00 | 0.441 | |||
| WBC (10^12/L) | 1.00 | 0.92–1.08 | 0.986 | |||
| HGB (g /L) | 1.00 | 0.99–1.01 | 0.769 | |||
| PLT (10^9/L) | 1.00 | 1.00–1.00 | 0.238 | |||
| ANC (10^9/L) | 0.97 | 0.92–1.03 | 0.360 | |||
| ALC (10^9/L) | 0.86 | 0.50–1.49 | 0.588 | |||
| Alpha fetoprotein (ng/ml), < 400 versus ≥ 400 | 1.57 | 0.92–2.69 | 0.101 | |||
| Max tumor size (cm) | 1.03 | 0.99–1.09 | 0.170 | |||
| Tumor number, ≥ 3 versus < 3 | 1.49 | 0.87–2.55 | 0.148 | |||
| Macrovascular invasion, yes versus no | 1.65 | 0.90–3.00 | 0.104 | |||
| Extrahepatic metastasis, yes versus no | 0.98 | 0.57–1.68 | 0.936 | |||
| BCLC stage | 1.28 | 0.79–2.07 | 0.312 | |||
| A | ||||||
| B | ||||||
| C | ||||||
| Dose per fraction | 0.98 | 0.72–1.33 | 0.875 | |||
| GTV (cc/ml) | 1.00 | 1.00–1.00 | 0.372 | |||
| EQD28 (Gy) | 1.00 | 0.98–1.03 | 0.653 | |||
| NLV (cc/ml) | 1.00 | 1.00–1.00 | 0.573 | |||
| Dmean (Gy) | 1.04 | 0.99–1.09 | 0.143 | |||
| Prior treatment | ||||||
| TACE | 1.71 | 0.88–3.32 | 0.116 | |||
| RFA | 0.33 | 0.08–1.37 | 0.128 | |||
| Surgical resection | 0.54 | 0.30–0.97 | 0.039 | 0.60 | 0.33–1.08 | 0.088 |
| Systemic therapy | 0.65 | 0.34–1.21 | 0.211 | |||
| ncRILD | 3.32 | 1.81–6.08 | < 0.0001 | 3.08 | 1.67–5.66 | < 0.001 |
ALBI, albumin–bilirubin; ALC, absolute lymphocyte count; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; Dmean, mean dose to the normal liver; ECOG PS, Eastern Cooperative Oncology Group-performance status; EQD2, equivalent dose in 2‑Gy fractions; GTV, gross tumor volume; HGB, hemoglobin; NLV, normal liver volume; OR, odds ratio; PLT, platelets; PT, prothrombin time; RFA, radiofrequency ablation; RT, radiotherapy; TACE, transcatheter chemoembolization; WBC, white blood cells; 8, using LQ model, α/β = 8 Gy